Zura Bio (NASDAQ:ZURA) Research Coverage Started at Wedbush

Wedbush assumed coverage on shares of Zura Bio (NASDAQ:ZURA) in a research note released on Monday, MarketBeat reports. The firm issued an outperform rating and a $15.00 price target on the stock.

Several other research analysts have also commented on ZURA. Wall Street Zen lowered shares of Zura Bio from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. Leerink Partners upgraded shares of Zura Bio to a “strong-buy” rating in a report on Sunday, November 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a report on Friday, January 9th. Finally, Chardan Capital restated a “buy” rating and set a $10.00 price objective on shares of Zura Bio in a research note on Friday, November 14th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.60.

Zura Bio Trading Down 2.8%

Shares of NASDAQ:ZURA opened at $6.26 on Monday. The firm has a market cap of $407.03 million, a price-to-earnings ratio of -9.63 and a beta of 0.21. The stock’s 50-day moving average price is $5.11 and its two-hundred day moving average price is $3.65. Zura Bio has a 12-month low of $0.97 and a 12-month high of $6.88.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). As a group, research analysts forecast that Zura Bio will post -0.65 earnings per share for the current fiscal year.

Institutional Trading of Zura Bio

Institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its holdings in shares of Zura Bio by 78.7% during the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company’s stock valued at $4,893,000 after acquiring an additional 2,052,732 shares during the period. Boothbay Fund Management LLC bought a new stake in Zura Bio in the third quarter worth about $3,568,000. Suvretta Capital Management LLC grew its position in Zura Bio by 12.6% in the third quarter. Suvretta Capital Management LLC now owns 5,472,891 shares of the company’s stock worth $23,698,000 after buying an additional 611,952 shares during the last quarter. Ameriprise Financial Inc. acquired a new position in shares of Zura Bio in the 3rd quarter worth $2,165,000. Finally, Atika Capital Management LLC acquired a new stake in Zura Bio during the 3rd quarter worth about $1,195,000. 61.14% of the stock is currently owned by institutional investors and hedge funds.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.